Ensysce Biosciences AI Stock Analysis
Want to see ENSC full AI Analyst Report?
Ensysce Biosciences (ENSC) AI Stock Analysis
Ensysce Biosciences
(NASDAQ:ENSC)
The overall score of 39 reflects a very high-risk, distressed micro-cap biotechnology company. The most significant factor is the dire financial performance, marked by massive losses and unsustainable cash burn that threaten the company's viability. This is compounded by a bearish technical trend and significant corporate event risks, including ongoing Nasdaq delisting hurdles. The recent financing provides a short-term lifeline but does not resolve the fundamental lack of a path to profitability.
Ensysce Biosciences (ENSC) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $7.47M
- Dividend Yield
- ―
- Average Volume (3M)
- 537.57K
- Price to Earnings (P/E)
- -0.1
- Beta (1Y)
- 3.28
- Revenue Growth
- 37.91%
- EPS Growth
- 1.72%
- Country
- US
- Employees
- 9
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Ensysce Biosciences Business Overview & Revenue Model
Company Description
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to developing novel prescription drugs for the treatment of severe pain in the United States, with a specific focus on preventing opioid addiction, misuse, abuse, and overdos...
How the Company Makes Money
Ensysce Biosciences is a clinical-stage company and does not have publicly established, recurring product sales in the way commercial-stage pharmaceutical companies do; as a result, any routine revenue from marketed drugs is not available. The compan...
Ensysce Biosciences Earnings Call Summary
The earnings call highlighted significant clinical achievements, including FDA breakthrough designations and successful trial completions, against a backdrop of financial challenges and reduced funding. The company is making progress toward its goals but needs additional funding to maintain momentum.
Q4-2023 Updates
Positive Updates
Negative Updates
Company Guidance
During Ensysce Biosciences' Q4 2023 earnings call, the company provided detailed guidance on its advancements and future plans. Ensysce reported significant clinical progress with its next-generation opioid analgesics, focusing on the PF614 and PF614-MPAR products. The company completed five clinical trials for PF614, including a human abuse potential study and an analgesic efficacy study. Ensysce plans to initiate Phase III trials for PF614 in the second half of 2024, following FDA feedback. They also received breakthrough therapy designation for PF614-MPAR, highlighting its potential to prevent opioid overdose. Financially, Ensysce ended 2023 with $1.1 million in cash, supplemented by early 2024 warrant exercises and plans to raise additional funds before starting Phase III trials. The company’s R&D expenses decreased in 2023, totaling $7.6 million, with a focus on optimizing manufacturing and preparing for pivotal clinical trials.
Ensysce Biosciences Financial Statement Overview
Summary
Financial health is critically weak. The company is pre-revenue with a net loss of $91.2M, deeply negative margins, and an operating cash burn of $8.4M. The recent recapitalization provides only a temporary equity buffer, and the business is entirely dependent on external funding with no path to profitability.
Income Statement
8Very NegativeBalance Sheet
35NegativeCash Flow
10Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.23M | 5.07M | 0 | 0 | 0 | 0 |
| Gross Profit | 1.61M | -5.31M | 0 | 0 | 0 | 0 |
| EBITDA | -90.99M | -10.15M | -6.70M | -10.27M | -24.10M | -27.85M |
| Net Income | -91.01M | -10.18M | -7.99M | -10.61M | -24.17M | -29.08M |
Balance Sheet | ||||||
| Total Assets | 30.95M | 7.45M | 5.60M | 2.71M | 5.89M | 16.42M |
| Cash, Cash Equivalents and Short-Term Investments | 29.67M | 4.31M | 3.50M | 1.12M | 3.15M | 12.26M |
| Total Debt | 154.87K | 306.71K | 301.66K | 854.70K | 4.43M | 17.21M |
| Total Liabilities | 3.84M | 4.57M | 2.22M | 3.36M | 9.91M | 24.58M |
| Stockholders Equity | 27.44M | 3.21M | 3.71M | -322.86K | -3.71M | -7.88M |
Cash Flow | ||||||
| Free Cash Flow | -8.44M | -7.93M | -7.50M | -10.78M | -17.89M | -8.24M |
| Operating Cash Flow | -8.39M | -7.81M | -7.50M | -10.78M | -17.89M | -8.24M |
| Investing Cash Flow | 11.39M | -123.64K | 0 | 0 | 4,500 | 0 |
| Financing Cash Flow | 25.23M | 8.74M | 9.88M | 8.76M | 8.77M | 20.31M |
Ensysce Biosciences Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ENSC, the sentiment is Negative. The current price of 0.38 is below the 20-day moving average (MA) of 0.41, below the 50-day MA of 0.44, and below the 200-day MA of 0.40, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 42.86 is Neutral, neither overbought nor oversold. The STOCH value of 70.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ENSC.
Ensysce Biosciences Risk Analysis
Ensysce Biosciences disclosed 49 risk factors in its most recent earnings report. Ensysce Biosciences reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
2 New RisksEnsysce Biosciences Peers Comparison
Overall Rating
ENSC39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 39Underperform | $7.47M | -0.07 | -1232.64% | ― | 37.91% | 1.72% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| ENSC | Ensysce Biosciences, Inc. | 0.38 | -1.45 | -79.07% | |
| SILO | Silo Pharma Inc | 1.71 | -4.21 | -71.14% | |
| ALZN | Alzamend Neuro, Inc. | 1.13 | -1.18 | -51.08% |
Ensysce Biosciences Corporate Events
Ensysce Biosciences Announces CEO Transition and Director Resignation
NeutralOn October 29, 2026, CEO Lynn Kirkpatrick agreed to relinquish the CEO title and assume COO responsibilities after the December 14, 2026 annual meeting; President James Morrisson was previously set to become CEO. The transition would be delayed if th...
Ensysce Biosciences Updates Series C Preferred Stock Terms
NeutralOn August 5, 2026, Ensysce Biosciences filed a Certificate of Designation for its Series C Non-Voting Convertible Preferred Stock with Delaware authorities, followed by a Certificate of Correction on August 6, 2026. These actions established key pref...
Ensysce Biosciences Gains Nasdaq Equity Compliance, Faces New Listing Hurdles
NegativeOn May 21, 2026, Ensysce Biosciences disclosed that Nasdaq had warned the company over non-compliance with the $2.5 million stockholders’ equity requirement as of March 31, 2026, triggering a potential delisting process unless a remediation plan was...
Ensysce Biosciences Seeks Extended Nasdaq Compliance Grace Period
PositiveOn August 5, 2026, Ensysce Biosciences acquired Cy Biopharma, Inc. and entered into a Securities Purchase Agreement to issue 120,260 shares of Series C Preferred Stock for approximately $43 million in financing, structured in two tranches. At the ini...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 13, 2026
